



Semi-annual report as at 31 March 2023 UniValueFonds: Global

Management Company: Union Investment Luxembourg S.A.

In case of discrepancy between the English and German version, the German version shall prevail.

Contents

| | Page |
|---|------|
| Preface | 3 |
| UniValueFonds: Global | 5 |
| Performance of the fund | 5 |
| Breakdown by country | 5 |
| Breakdown by sector | 5 |
| Composition of the fund's assets | 6 |
| Attribution to the unit classes | 6 |
| Schedule of assets | 7 |
| Exchange rates | 10 |
| Notes on the report as at 31 March 2023 | 11 |
| (attachment) | |
| Other information of the Management Company | 13 |
| Management and Organisation | 16 |

Note

Units may be acquired only on the basis of the current sales prospectus and the key investor information accompanied by the most recent annual report and, if available, the semi-annual report.

Union Investment – devoted to your interests

The Union Investment Group manages assets of about EUR 425 billion, making it one of Germany's largest investment companies for both private and institutional investors. It is the expert for fund management within the cooperative finance association. Around 5.3 million private and institutional investors have placed their trust in us as their partner for fund-based investments.

Today, the idea behind the foundation of the group in 1956 is more topical than ever: private investors should have the opportunity to benefit from economic developments –even with only small monthly savings contributions. The interests of these investors have always been one of our primary concerns and, together with our roughly 4,430 employees, we are committed to looking after them. Around 1,350 public-investment and specialist funds offer private and institutional investors solutions tailored to their individual requirements. These include share, bond and money-market funds, open-end real estate funds, and intelligent solutions for asset accumulation, risk management and private and corporate pension schemes.

Partner cooperation with advisers from the Volksbanken and Raiffeisen banks forms the basis of Union Investment's strong investor focus. In approximately 7,500 branches, our employees provide personalised advice on all investment matters.

The best proof of the our fund management's quality: Our awards for individual funds –and solid performance in sector ratings. Coalition Greenwich recognised Union Investment as a "Greenwich Quality Leader" in overall German institutional investment management for the fifth time. The trade journal Capital again gave Union Investment the highest rating of five stars in its Fund Compass in February 2023 and recognised it as the top fund management company. This makes us the only fund management company to have received this prestigious award for the 21st time in a row since it was first awarded in 2002.

Union Investment Real Estate also received the Scope Alternative Investment Award 2023 in the Retail Real Estate Germany category. Union Investment was also named the best fund management company for dividend equity funds at the Scope Investment Awards 2023. UniGlobal also won an award in the international equity fund category. We won the German Fund Champions 2023 award again in the "Equities" category, which was awarded by f-fex and finanzen.net. The TELOS ESG Company Check 2022 also confirms that Union Investment meets the highest standards in sustainability. We consider the "PLATINUM" rating level to be a very professional and clearly comprehensible integration of sustainability aspects at various levels.

Bond markets driven by monetary policy

The central banks continued to be the focus of the bond markets in the half year under review. Weak economic data initially gave rise to hopes that the monetary authorities might be less restrictive in future. In addition, there were initial signs of decreasing inflation momentum. Investors therefore looked very closely at the US inflation rate. In October and November 2022, this declined, and inflation also rose less rapidly in the eurozone. The result was significantly lower yields accompanied by high price gains. Towards the end of the year, however, the government bond markets came under considerable pressure, especially in Europe. After unexpectedly robust economic data, global central banks held out the prospect of further interest rate steps.

At the beginning of 2023, investors initially reacted with relief to the easing of inflationary pressure. Expectations of a less restrictive monetary policy initially led to declining yields. In the further course, some economic data turned out better than expected. For example, company purchasing managers were more optimistic about the future again. Furthermore, fear of a shortage of skilled workers has so far not led to waves of redundancies. With these requirements, more and more doubts arose as to whether monetary policy was already restrictive enough. In addition, core inflation proved to be persistent, suggesting high underlying price pressures. Yields quickly rose again significantly. In the USA, the yield on two-year government bonds climbed above the five percent mark at times.

But only a short time later, the Silicon Valley Bank (SVB) from the USA caused a stir and uncertainty. A little later, the globally networked Swiss bank Credit Suisse also stumbled. Both institutions had run into difficulties due to high outflows on the deposit side and ultimately had to be rescued by the state. In this context, memories of the 2008 financial crisis came up and investors took refuge in government bonds. Yields fell significantly in a very short space of time. At the same time, many market participants adjusted their expectations for monetary policy, as the bankruptcy of the SVB was also favoured by the rapid rise in interest rates. Investors therefore began to doubt that the monetary authorities would raise interest rates significantly further, as the turmoil had already caused a tightening of financing conditions.

Measured against the J.P. Morgan Global Bond US Index, US government bonds ultimately rose 3.7% during the reporting period. Euro government bonds, as measured by the iBoxx Euro Sovereigns Index, only went up by 0.3%.

For a long time, the higher risk appetite boosted European corporate bonds. These rose by 2.9% as measured by the ICE BofA Merrill Lynch Euro Corporate Index (ER00). Emerging market bonds saw declining risk premiums and recorded high demand at the beginning of the year. Measured by the J.P. Morgan EMBI Global Diversified Index, there was a strong increase of 10.1% here.

Global equities trending positive

Hopes of an imminent end to the cycle of interest rate hikes by the major central banks boosted share prices in October and November 2022. The weakening of inflationary pressures in the USA gave cause for optimism. Inflation had peaked at 9.1% month-on-month in June and had since entered a slow but steady decline. Since the beginning of the fourth quarter of 2022, core inflation, which is adjusted for food and energy prices that are highly susceptible to fluctuations, has also been declining at a high level. In the eurozone, too, there were initially more indications that inflation might have peaked.

Nevertheless, the central banks remained on their path of interest rate hikes, but slowed down the pace in December. While the US Federal Reserve and the European Central Bank (ECB) raised key interest rates in the US and the eurozone by 75 basis points each at the beginning of October, both only followed up with a 50 basis point increase in December. The central bankers emphasised that an end to the interest rate hikes is not yet in sight, as the path of inflation back to near the central bank's targets (around two percent) is still a long one. The clear recovery on the capital markets was thus dampened again in December.

The start of 2023 was generally positive on the global stock markets, but was marked by strong turbulence and losses in the banking sector in March. While at the beginning of the year a good reporting season and an easing of energy prices, among other things, boosted share prices, the difficulties of the US Silicon Valley Bank in March and a few days later concerns about the stability of Credit Suisse led to significant market distortions. Overall, the great concern about a renewed banking crisis unsettled market participants. However, the rapid and decisive intervention and effective relief measures by central banks, governments and regulators were able to stabilise the market again in the further course of the year.

Despite the turbulence in March, the global stock markets recorded positive price gains overall in the half year under review. The MSCI World index gained 14.6% in local currency. In the USA, the S&P 500 Index also climbed by 14.6% and the Dow Jones Industrial Average improved by 15.8% (both in local currency). The gains in Europe were even more pronounced. The EURO STOXX 50 Index gained 30%, and the leading German index DAX 40 gained 29%. The Nikkei 225 Index in Japan increased by 8.1% in local currency. The stock exchanges of the emerging markets rose by 9.7% (as measured by the MSCI Emerging Markets Index in local currency).

Important information:

Unless otherwise specified, the data source for the financial indices is Refinitiv. All unit performance data on the following pages is taken from Union Investment's own calculations in accordance with the method applied by the German Investment Funds Association (BVI), unless otherwise specified. The ratios illustrate past performance. Future results may be either higher or lower.

Detailed information on the Management Company and the Depositary of the investment fund (the "Fund") can be found on the last pages of this report.

Class A Security Ident. No. 631010 ISIN-Code LU0126315885 Class -net- A Security Ident. No. 631011 ISIN-Code LU0126316180 Class C Security Ident. No. 634555 ISIN-Code LU0126316347 Class I Security Ident. No. A3CS16 ISIN-Code LU2355246864 Class EUR acc RF Security Ident. No. A3CS17 ISIN-Code LU2355246948 Semi-annual report 01.10.2022 - 31.03.2023

Class USD acc (liquidated) Security Ident. No. A3CS18 ISIN-Code LU2355247086

Performance in percent ¹⁾

| | 6 months | 1 year | 3 years | 10 years |
|------------------|----------|--------|---------|----------|
| Class A | 5.51 | -0.88 | 69.35 | 143.73 |
| Class -net- A | 5.33 | -1.16 | 68.33 | 136.70 |
| Class C | 5.35 | -1.12 | 68.49 | 137.65 |
| Class I | 5.78 | -0.22 | 10.612) | - |
| Class EUR acc RF | 6.17 | 1.09 | 13.192) | - |

 Based on published unit values (BVI method). The information and figures contained in this report are based on the past and do not provide any indication of future developments.

2) Since launch.

Breakdown by country ¹⁾

| United States of America | 55.39 % |
|--------------------------------|-----------|
| Germany | 6.81 % |
| France | 5.86 % |
| Great Britain | 5.84 % |
| Japan | 5.04 % |
| Canada | 3.57 % |
| Netherlands | 2.54 % |
| Spain | 1.55 % |
| Bermuda | 1.51 % |
| South Korea | 1.39 % |
| Curacao | 1.33 % |
| Luxembourg | 1.04 % |
| Austria | 0.97 % |
| Belgium | 0.54 % |
| Denmark | 0.54 % |
| Finland | 0.52 % |
| Hong Kong | 0.52 % |
| Portfolio assets | 94.96 % |
| | |
| Futures | -0.03 % |
| | |
| Bank deposits | 4.94 % |
| Other assets/Other liabilities | 0.13 % |
| Fund assets | 100.00 % |
| | 100.00 /8 |

1) Due to rounding differences in each position, the sum may deviate from the actual value.

Breakdown by sector ¹⁾

| Pharmaceuticals, Biotechnology & Life Sciences | 11.94 % |
|--|----------|
| Banks | 9.45 % |
| Energy | 9.42 % |
| Insurance | 6.63 % |
| Food, Beverage & Tobacco | 6.56 % |
| Raw materials and supplies | 6.42 % |
| Health Care Equipment & Services | 6.34 % |
| Capital Goods | 4.99 % |
| Telecommunication Services | 4.95 % |
| Utilities | 4.34 % |
| Semiconductors & Semiconductor Equipment | 4.28 % |
| Transportation | 3.48 % |
| Household & Personal Products | 3.40 % |
| Software & Services | 3.06 % |
| Technology Hardware & Equipment | 2.87 % |
| Automobiles & Components | 2.82 % |
| Food & Staples Retailing | 1.35 % |
| Media & Entertainment | 1.09 % |
| Consumer Durables & Apparel | 0.58 % |
| Consumer Services | 0.51 % |
| Retailing | 0.48 % |
| Portfolio assets | 94.96 % |
| Futures | -0.03 % |
| Bank deposits | 4.94 % |
| Other assets/Other liabilities | 0.13 % |
| Fund assets | 100.00 % |

1) Due to rounding differences in each position, the sum may deviate from the actual value.

Composition of the fund's assets

as at 31 March 2023

| | EUR |
|--|------------------|
| Portfolio assets (Cost of securities: EUR 1,311,479,778.50) | 1,400,839,522.36 |
| Bank deposits | 72,937,984.29 |
| Other bank deposits | 1,511,644.51 |
| Interest receivable | 358,417.21 |
| Dividends receivable | 2,482,637.22 |
| Receivable on sale of units | 1,376,155.48 |
| Receivable on security trades | 81,480.25 |
| | 1,479,587,841.32 |
| Liabilities on repurchase of units | -257,584.63 |
| Unrealised losses from financial futures | -420,511.69 |
| Unrealised losses from forward exchange transactions | -1,840,144.73 |
| | |

Other liabilities

1,475,012,681.69

-2,056,918.58 **-4,575,159.63**

626,404.004 85.81 EUR

Attribution to the unit classes

Class A

| Proportional fund assets | 760,887,869.71 EUR |
|--------------------------|--------------------|
| Units in circulation | 5,314,088.415 |
| Unit value | 143.18 EUR |
| Class -net- A | |
| Proportional fund assets | 447,222,887.51 EUR |
| Units in circulation | 3,157,625.784 |
| Unit value | 141.63 EUR |
| Class C | |
| Proportional fund assets | 53,749,814.73 EUR |

Unit value

Units in circulation

| Proportional fund assets | 200,474,305.99 EUR |
|--------------------------|--------------------|
| Units in circulation | 1,812,401.035 |
| Unit value | 110.61 EUR |

Class EUR acc RF

| Proportional fund assets | 12,677,803.75 EUR |
|--------------------------|-------------------|
| Units in circulation | 112,001.000 |
| Unit value | 113.19 EUR |

Schedule of assets as at 31 March 2023

| ISIN | Securities | | Additions | Disposals | Volume | Price | Market Value | Per cent of fund assets |
|------------------------------|--|-------------|--------------|-----------|--------------------|--------------------|-------------------------------------|----------------------------|
| | | | | | | | EUR | % 1 |
| Equities, rights o | n equities and profit-participation certificates | | | | | | | |
| Stock-exchange-tra | ded securities | | | | | | | |
| Austria | | | | | | | | |
| AT0000652011 | Erste Group Bank AG | EUR | 238,000 | 29,000 | 468,000 | 30.5000 | 14,274,000.00 | 0.9 |
| | | | | | | | 14,274,000.00 | 0.9 |
| Polaium | | | | | | | | |
| Belgium | | FUD | 21.000 | 0 | 125 700 | 62 2000 | 7 056 010 00 | 0.5 |
| 3E0003565737 | KBC Groep NV | EUR | 21,000 | 0 | 125,700 | 63.3000 | 7,956,810.00 7,956,810.00 | 0.5 0.5 |
| | | | | | | | .,, | |
| Bermuda | | | | | | | | |
| BMG0750C1082 | Axalta Coating Systems Ltd. | USD | 283,000 | 0 | 798,000 | 30.2900 | 22,251,146.09 | 1.5 |
| | | | | | | | 22,251,146.09 | 1.5 |
| Canada | | | | | | | | |
| CA1247651088 | CAE Inc. | CAD | 103,000 | 0 | 710,390 | 30.5600 | 14,768,379.86 | 1.0 |
| CA5503721063 | Lundin Mining Corporation | CAD | 1,126,912 | 0 | 2,465,182 | 9.1800 | 15,394,810.04 | 1.0 |
| CA5592224011 | Magna International Inc. | CAD | 45,000 | 0 | 259,000 | 72.3900 | 12,754,428.57 | 0.8 |
| CA7800871021 | Royal Bank of Canada | CAD | 15,000 | 10,000 | 112,800 | 129.2500 | 9,917,959.18 | 0.6 |
| | | | | | | | 52,835,577.65 | 3.5 |
| Curacao | | | | | | | | |
| AN8068571086 | Schlumberger NV (Schlumberger Ltd.) | USD | 63,510 | 146,000 | 434,831 | 49.1000 | 19,654,056.98 | 1.3 |
| 410000571000 | Schlumberger IVV (Schlumberger Etd.) | 030 | 03,510 | 140,000 | 100,404 | 45.1000 | 19,654,056.98 | 1.3 |
| | | | | | | | 10,00 1,000100 | |
| Denmark | | | | | | | | |
| DK0060738599 | Demant AS | DKK | 247,600 | 0 | 247,600 | 240.2000 | 7,983,880.15 | 0.5 |
| | | | | | | | 7,983,880.15 | 0.54 |
| Finland | | | | | | | | |
| FI0009005987 | UPM Kymmene Corporation | EUR | 123,090 | 158,000 | 248,090 | 30.9500 | 7,678,385.50 | 0.5 |
| | | 2011 | 123,030 | 130,000 | 2 10,000 | 50.5500 | 7,678,385.50 | 0.5 |
| | | | | | | | | |
| France | | | | | | | | |
| FR0000120628 | AXA S.A. | EUR | 60,000 | 227,500 | 367,080 | 28.1650 | 10,338,808.20 | 0.7 |
| FR0000125007 | Compagnie de Saint-Gobain S.A. | EUR | 31,000 | 0 | 178,000 | 52.3200 | 9,312,960.00 | 0.6 |
| FR0014008VX5 FR0000121147 | EuroAPI SAS Faurecia SE | EUR | 0 326,000 | 218,000 | 691,690 | 10.5250 19.9450 | 10.53 13,795,757.05 | 0.0 |
| FR0000121147 | Sanofi S.A. | EUR | 149,000 | 218,000 | 149,000 | 100.2400 | 14,935,760.00 | 1.0 |
| FR0000120271 | TotalEnergies SE | EUR | 48,000 | 0 | 414,291 | 54.3600 | 22,520,858.76 | 1.5 |
| FR0000125486 | VINCI S.A. | EUR | 10,000 | 0 | 145,800 | 105.7200 | 15,413,976.00 | 1.0 |
| | | | | | | | 86,318,130.54 | 5.8 |
| ~ | | | | | | | | |
| Germany | | FU P | | 107 000 | 205 | 40.0 | 10 (27 (| |
| DE000BASF111 | BASE SE | EUR | 172,000 | 107,830 | 385,400 | 48.3600 | 18,637,944.00 | 1.26 |
| DE000BAY0017 DE0006062144 | Bayer AG Covestro AG | EUR | 0 243,770 | 0 | 306,746 243,770 | 58.7200 38.1300 | 18,012,125.12 9,294,950.10 | 1.22 |
| DE0006062144 | Dte. Telekom AG | EUR | 243,770 | 0 | 1,070,000 | 22.3500 | 23,914,500.00 | 1.62 |
| DE00055773303 | Fraport AG Frankfurt Airport Services Worldwide | EUR | 93,000 | 32,000 | 294,000 | 46.3100 | 13,615,140.00 | 0.92 |
| DE000A0D9PT0 | MTU Aero Engines AG | EUR | 0 | 0 | 38,600 | 230.6000 | 8,901,160.00 | 0.60 |
| DE0008430026 | Münchener Rückversicherungs-Gesellschaft AG in München | EUR | 0 | 27,300 | 25,700 | 322.5000 | 8,288,250.00 | 0.5 |
| | | | | | | | 100,664,069.22 | 6.8 |
| | | | | | | | | |
| Great Britain | | | | | | | | |
| GB0030913577 | BT Group Plc. | GBP | 1,585,863 | 0 | 11,342,863 | 1.4580 | 18,827,293.09 | 1.2 |
| GB00BDCPN049 | Coca-Cola Europacific Partners Plc. | USD | 332,930 | 0 | 452,930 | 59.1900 | 24,679,118.75 | 1.6 |
| GB00BY9D0Y18 | Direct Line Insurance Group Plc. | GBP | 7,590,000 | 0 | 7,590,000 | 1.3750 | 11,880,976.78 | 0.81 |
| GB00BMJ6DW54 | Informa Plc. | GBP | 500,000 | 0 | 2,036,000 | 6.9260 | 16,053,433.52 | 1.0 |

The notes on the report form an integral part of this report.

| ISIN | Securities | | Additions | Disposals | Volume | Price | Market Value | Per cent of |
|--|---|--|--|---|---|---|---|--|
| | | | | | | | EUR | fund assets % ¹⁾ |
| GB00B24CGK77 | Reckitt Benckiser Group Plc. | GBP | 66,700 | 28,650 | 208,050 | 61.5800 | 14,585,290.30 | 0.99 |
| | | | | | | | 86,026,112.44 | 5.84 |
| Hong Kong | | | | | | | | |
| HK0000069689 | AIA Group Ltd. | HKD | 140,000 | 0 | 785,100 | 82.6500 | 7,609,681.49 | 0.52 |
| | | | 110,000 | | 705,100 | 02.0500 | 7,609,681.49 | 0.52 |
| | | | | | | | | |
| Japan JP3116000005 | | | 04.000 | 0 | 275 000 | 4 0 2 4 0 0 0 0 | 0.267.440.40 | 0.64 |
| JP3476480003 | Asahi Group Holdings Ltd. Dai-Ichi Life Holdings Inc. | JPY JPY | 84,000 62,280 | 313,000 | 275,000 | 4,924.0000 2,435.0000 | 9,367,440.10 8,460,870.31 | 0.64 |
| JP3914400001 | Murata Manufacturing Co. Ltd. | JPY | 277,690 | 0 | 277,690 | 8,040.0000 | 15,444,948.91 | 1.05 |
| JP3735400008 | Nippon Telegraph and Telephone Corporation | JPY | 0 | 0 | 264,000 | 3,962.0000 | 7,235,833.83 | 0.49 |
| JP3756100008 | Nitori Holdings Co. Ltd. | JPY | 64,000 | 0 | 64,000 | 15,930.0000 | 7,052,870.94 | 0.48 |
| JP3463000004 | Takeda Pharmaceutical Co. Ltd. | JPY | 388,000 | 0 | 388,000 | 4,350.0000 | 11,675,921.58 | 0.79 |
| JP365900008 | West Japan Railway Co. | JPY | 42,000 | 94,100 | 399,000 | 5,457.0000 | 15,062,499.18 | 1.02 |
| | | | | | | | 74,300,384.85 | 5.04 |
| Luxembourg | | | | | | | | |
| LU1598757687 | ArcelorMittal S.A. | EUR | 548,000 | 0 | 548,000 | 27.8700 | 15,272,760.00 | 1.04 |
| | | | | | | | 15,272,760.00 | 1.04 |
| Netherlands | | | | | | | | |
| NL0000009165 | Heineken NV | EUR | 33,000 | 21,250 | 145,750 | 99.0600 | 14,437,995.00 | 0.98 |
| NL0000009082 | Koninklijke KPN NV | EUR | 1,717,600 | 0 | 7,051,600 | 3.2560 | 22,960,009.60 | 1.56 |
| | | | | | | | 37,398,004.60 | 2.54 |
| South Korea | | | | | | | | |
| KR7005930003 | Samsung Electronics Co. Ltd. | KRW | 67,000 | 0 | 154,000 | 64,000.0000 | 6,970,116.12 | 0.47 |
| KR7000660001 | SK Hynix Inc. | KRW | 217,310 | 0 | 217,310 | 88,600.0000 | 13,616,100.63 | 0.92 |
| | | | | | | | 20,586,216.75 | 1.39 |
| Spain | | | | | | | | |
| ES0109067019 | Amadeus IT Group S.A. | EUR | 137,000 | 0 | 256,500 | 61.6600 | 15,815,790.00 | 1.07 |
| ES0113860A34 | Banco de Sabadell S.A. ²⁾ | | | 0 | 250,500 | | | 1.07 |
| | | EUK | 0 | 12,131,000 | 7,134,000 | 0.9888 | 7,054,099.20 | 0.48 |
| | | EUR | 0 | 12,131,000 | 7,134,000 | 0.9888 | 7,054,099.20 22,869,889.20 | 0.48 1.55 |
| United States of Am | | EUK | 0 | 12,131,000 | 7,134,000 | 0.9888 | | |
| United States of Am | ierica | | | | | | 22,869,889.20 | 1.55 |
| US00287Y1091 | ierica AbbVie Inc. | USD | 95,200 | 0 | 258,850 | 159.3700 | 22,869,889.20 37,975,627.82 | 1.55 2.57 |
| | ierica | | | | | | 22,869,889.20 | 1.55 |
| US00287Y1091 US0259321042 | lerica AbbVie lnc. American Financial Group lnc. | USD USD | 95,200 25,000 | 0 | 258,850 65,000 | 159.3700 121.5000 | 22,869,889.20 37,975,627.82 7,270,091.14 | 1.55 2.57 0.49 |
| US00287Y1091 US0259321042 US05722G1004 | lerica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. | USD USD USD | 95,200 25,000 567,430 | 0 0 0 | 258,850 65,000 567,430 | 159.3700 121.5000 28.8600 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 | 2.57 0.49 1.02 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 | AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation | USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 | 0 0 27,860 0 0 | 258,850 65,000 567,430 533,340 358,500 127,700 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 | 2.57 0.49 1.02 1.67 1.55 0.50 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 | AbbVie Inc. AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. | USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 | 0 0 27,860 0 0 0 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation | USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 | 0 0 27,860 0 0 0 0 0 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 | AbbVie Inc. AbeVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips | USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 | 0 0 27,860 0 0 0 0 18,700 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 147,520 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 | AbbVie Inc. AbeVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 94,800 29,700 31,000 227,100 28,420 9,860 | 0 0 27,860 0 0 0 0 18,700 0 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 147,520 65,490 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 | AbbVie Inc. AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. | USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 | 0 0 27,860 0 0 0 0 18,700 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 147,520 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 147,520 65,490 169,400 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 | eerica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 | 0 0 27,860 0 0 0 18,700 0 69,000 0 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 | 1.55 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 | eerica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 0 0 0 0 0 0 0 0 30,000 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 2442,900 66,000 276,700 29,210 0 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Huntington Bancshares Inc. | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 0 0 0 0 0 30,000 0 926,000 0 0 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 |
| US00287Y1091 US0259321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US4581401001 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Huntington Bancshares Inc. Intel Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 |
| US00287Y1091 US0229321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US4581401001 US4592001014 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Huntington Bancshares Inc. Intel Corporation International Business Machines Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 69,000 0 0 30,000 0 30,000 0 926,000 0 0 32,500 | 258,850 65,000 567,430 358,500 127,700 413,010 413,010 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 |
| US00287Y1091 US0229321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US4581401001 US4592001014 US46625H1005 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exelon Corporation Exelon Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Huntington Bancshares Inc. Intel Corporation International Business Machines Corporation JPMorgan Chase & Co. | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 25,330 82,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 69,000 0 0 30,000 0 30,000 0 926,000 0 32,500 8,800 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 372,540 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 130.3100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 44,689,024.58 | 1.55 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 3.03 |
| US00287Y1091 US0229321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US4581401001 US4592001014 US4592001014 US46625H1005 US4932671088 | erica AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConocoPhillips Constellation Brands Inc. CVS Health Corporation Exelon Corporation Exelon Corporation Exxon Mobil Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Huntington Bancshares Inc. Intel Corporation International Business Machines Corporation JPMorgan Chase & Co. Keycorp | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 25,330 82,000 | 0 0 27,860 0 0 0 0 18,700 0 69,000 0 69,000 0 0 30,000 0 30,000 0 926,000 0 32,500 8,880 200,000 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 372,540 666,000 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 130.3100 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 44,689,024.58 7,675,890.64 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 3.03 0.52 |
| US00287Y1091 US00287Y1091 US0259321042 US1722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US4581401001 US4582001014 US4582001014 US4592001014 US4932671088 US4943681035 US4990491049 US5178341070 | AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConcoPhillips Conscellation Brands Inc. CVS Health Corporation Exelon Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Intel Corporation Intel Corporation JPMorgan Chase & Co. Keycorp Kimberly-Clark Corporation Holdings Inc. Las Vegas Sands Corporation 2) | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 25,330 82,000 866,000 11,000 172,000 0 | 0 0 27,860 0 0 0 0 0 18,700 0 69,000 0 69,000 0 0 30,000 0 926,000 0 926,000 0 32,500 8,800 200,000 0 0 0 41,410 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 372,540 666,000 143,000 296,000 141,570 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 130.3100 12.5200 134.2200 56.5800 57.4500 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 44,689,024.58 7,675,890.64 17,668,655.07 15,417,177.58 7,487,062.97 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 3.03 0.52 1.20 1.05 0.51 |
| US00287Y1091 US0229321042 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US42809H1077 US4461501045 US42809H1077 US4461501045 US4581401001 US4582001014 US4582001014 US492671088 US493681035 US4990491049 US5178341070 US5218652049 | AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConcoPhillips Conscellation Brands Inc. CVS Health Corporation Exelon Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Intel Corporation Intel Corporation JPMorgan Chase & Co. Keycorp Kimberly-Clark Corporation Holdings Inc. Las Vegas Sands Corporation 2 ³ Lear Corporation | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 25,330 82,000 82,000 11,000 172,000 0 39,300 | 0 0 27,860 0 0 0 0 0 18,700 0 0 69,000 0 0 0 0 0 30,000 0 926,000 0 926,000 0 32,500 8,800 200,000 0 0 0 41,410 9,940 | 258,850 65,000 567,430 533,340 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 372,540 666,000 143,000 296,000 141,570 116,860 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 130.3100 12.5200 134.2200 56.5800 57.4500 139.4900 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 44,689,024.58 7,675,890.64 17,668,655.07 15,417,177.58 7,487,062.97 15,005,800.79 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 3.03 0.52 1.20 1.05 0.51 1.02 |
| US00287Y1091 US00287Y1091 US05722G1004 US1011371077 US1101221083 US15135B1017 US17275R1023 US1258961002 US20825C1045 US21036P1084 US1266501006 US30161N1019 US30231G1022 US3755581036 US40412C1018 US40412C1018 US42809H1077 US4461501045 US4581401001 US4592001014 US4592001014 US459201014 US4932671088 US493681035 US4990491049 US5178341070 | AbbVie Inc. American Financial Group Inc. Baker Hughes Co. Boston Scientific Corporation Bristol-Myers Squibb Co. Centene Corporation Cisco Systems Inc. CMS Energy Corporation ConcoPhillips Conscellation Brands Inc. CVS Health Corporation Exelon Corporation Gilead Sciences Inc. HCA Healthcare Inc. Hess Corporation Intel Corporation Intel Corporation JPMorgan Chase & Co. Keycorp Kimberly-Clark Corporation Holdings Inc. Las Vegas Sands Corporation 2) | USD USD USD USD USD USD USD USD USD USD | 95,200 25,000 567,430 76,200 94,800 29,700 31,000 227,100 28,420 9,860 51,000 442,900 66,000 276,700 29,210 0 354,000 512,000 25,330 82,000 866,000 11,000 172,000 0 | 0 0 27,860 0 0 0 0 0 18,700 0 69,000 0 69,000 0 0 30,000 0 926,000 0 926,000 0 32,500 8,800 200,000 0 0 0 41,410 | 258,850 65,000 567,430 358,500 127,700 413,010 419,700 147,520 65,490 169,400 442,900 322,000 276,700 40,210 65,400 818,300 512,000 182,130 372,540 666,000 143,000 296,000 141,570 | 159.3700 121.5000 28.8600 50.0300 69.3100 63.2100 52.2750 61.3800 99.2100 225.8900 74.3100 41.8900 109.6600 82.9700 263.6800 132.3400 11.2000 32.6700 131.0900 130.3100 12.5200 134.2200 56.5800 57.4500 | 22,869,889.20 37,975,627.82 7,270,091.14 15,075,052.75 24,563,196.35 22,873,639.88 7,430,651.75 19,874,894.37 23,714,614.75 13,472,760.01 13,618,278.65 11,588,064.07 17,079,150.33 32,505,311.61 21,133,939.98 9,760,262.17 7,967,445.46 8,436,859.06 15,398,177.30 21,978,663.08 44,689,024.58 7,675,890.64 17,668,655.07 15,417,177.58 7,487,062.97 | 2.57 0.49 1.02 1.67 1.55 0.50 1.35 1.61 0.91 0.92 0.79 1.16 2.20 1.43 0.66 0.54 0.57 1.04 1.49 3.03 0.52 1.20 1.05 0.51 |

The notes on the report form an integral part of this report.

| ISIN | Securities | | Additions | Disposals | Volume | Price | Market Value | |
|------------------------|---|-----|-----------|-----------|---------|----------|------------------|--------------------------------|
| | | | | | | | EUR | fund assets % ¹⁾ |
| US5951121038 | Micron Technology Inc. | USD | 182,000 | 0 | 336,000 | 60.3400 | 18,663,573.60 | 1.27 |
| US6826801036 | Oneok Inc. [New] | USD | 0 | 0 | 240,000 | 63.5400 | 14,038,111.02 | 0.95 |
| US68622V1061 | Organon & Co. | USD | 153,000 | 0 | 573,500 | 23.5200 | 12,417,122.34 | 0.84 |
| US7010941042 | Parker-Hannifin Corporation | USD | 31,000 | 0 | 31,000 | 336.1100 | 9,591,650.56 | 0.65 |
| US7181721090 | Philip Morris International Inc. | USD | 75,500 | 0 | 317,500 | 97.2500 | 28,423,893.03 | 1.93 |
| US7433151039 | Progressive Corporation | USD | 41,400 | 0 | 177,100 | 143.0600 | 23,323,139.10 | 1.58 |
| US6936561009 | PVH Corporation | USD | 16,000 | 22,100 | 104,900 | 89.1600 | 8,609,853.63 | 0.58 |
| US83088M1027 | Skyworks Solutions Inc. | USD | 142,500 | 0 | 142,500 | 117.9800 | 15,476,525.82 | 1.05 |
| US8485741099 | Spirit Aerosystems Holdings Inc. 2) | USD | 100,000 | 0 | 490,800 | 34.5300 | 15,600,961.06 | 1.06 |
| US87612G1013 | Targa Resources Corporation | USD | 17,450 | 0 | 207,450 | 72.9500 | 13,931,213.75 | 0.94 |
| US0200021014 | The Allstate Corporation | USD | 20,000 | 0 | 135,228 | 110.8100 | 13,794,177.19 | 0.94 |
| US1890541097 | The Clorox Co. | USD | 68,950 | 0 | 122,950 | 158.2400 | 17,909,976.99 | 1.21 |
| US1912161007 | The Coca-Cola Co. | USD | 18,700 | 293,000 | 109,180 | 62.0300 | 6,234,406.15 | 0.42 |
| US4165151048 | The Hartford Financial Services Group Inc. | USD | 7,800 | 0 | 106,800 | 69.6900 | 6,851,599.01 | 0.46 |
| US6934751057 | The PNC Financial Services Group Inc. | USD | 50,000 | 41,000 | 147,000 | 127.1000 | 17,199,392.43 | 1.17 |
| US9078181081 | Union Pacific Corporation | USD | 6,800 | 24,000 | 39,100 | 201.2600 | 7,244,100.16 | 0.49 |
| US9311421039 | Walmart Inc. | USD | 33,000 | 0 | 146,530 | 147.4500 | 19,889,393.81 | 1.35 |
| US92939U1060 | WEC Energy Group Inc. | USD | 265,500 | 0 | 265,500 | 94.7900 | 23,167,398.51 | 1.57 |
| US9497461015 | Wells Fargo & Co. | USD | 176,000 | 33,000 | 642,000 | 37.3800 | 22,091,466.45 | 1.50 |
| US96208T1043 | Wex Inc. | USD | 10,000 | 38,600 | 43,230 | 183.8900 | 7,318,019.61 | 0.50 |
| US96145D1054 | WRKCo Inc. | USD | 70,310 | 0 | 223,310 | 30.4700 | 6,263,698.52 | 0.42 |
| US98956P1021 | Zimmer Biomet Holdings Inc. | USD | 35,600 | 11,950 | 199,650 | 129.2000 | 23,745,539.91 | 1.61 |
| | | | | | | | 817,160,416.90 | 55.39 |
| Stock-exchange-trad | ded securities | | | | | | 1,400,839,522.36 | 94.96 |
| Equities, rights on ec | quities and profit-participation certificates | | | | | | 1,400,839,522.36 | 94.96 |
| Portfolio assets | | | | | | | 1,400,839,522.36 | 94.96 |
| Futures | | | | | | | | |
| Long positions | | | | | | | | |
| JPY | | | | | | | | |
| Tokyo Stock Price (TO | OPIX) Index Future Juni 2023 | | 150 | 0 | 150 | | 292,278.52 | 0.02 |
| | | | | | | | 292,278.52 | 0.02 |
| Long positions | | | | | | | 292,278.52 | 0.02 |
| Short positions | | | | | | | | |
| EUR | | | | | | | | |
| Euro Stoxx 50 Price I | ndex Future Juni 2023 | | 0 | 430 | -430 | | -712,790.21 | -0.05 |
| | | | | | | | -712,790.21 | -0.05 |
| Short positions | | | | | | | -712,790.21 | -0.05 |
| Futures | | | | | | | -420,511.69 | -0.03 |
| Bank deposits - curre | | | | | | | 72,937,984.29 | 4.94 |
| Other assets/Other I | liabilities | | | | | | 1,655,686.73 | 0.13 |
| Fund assets in EUR | | | | | | | 1,475,012,681.69 | 100.00 |

1) Due to rounding differences in each position, the sum may deviate from the actual value.

2) The securities indicated have been lent either in part or in full.

Forward exchange transactions

On the 31st of March, 2023 the following open forward exchange transactions were outstanding:

| Currency | | Monetary amount | Market Value | Per cent of fund assets |
|----------|----------------|-----------------|----------------|----------------------------|
| | | | EUR | % |
| AUD/EUR | Currency buys | 49,990,000.00 | 30,816,821.46 | 2.09 |
| CAD/EUR | Currency buys | 171,516.00 | 116,591.10 | 0.01 |
| CHF/EUR | Currency buys | 27,000,000.00 | 27,237,840.83 | 1.85 |
| GBP/EUR | Currency buys | 20,380,000.00 | 23,186,756.93 | 1.57 |
| HKD/EUR | Currency buys | 41,370,000.00 | 4,851,712.57 | 0.33 |
| JPY/EUR | Currency buys | 945,900,000.00 | 6,555,313.66 | 0.44 |
| USD/EUR | Currency buys | 163,439,129.30 | 150,304,748.82 | 10.19 |
| EUR/CAD | Currency sales | 11,400,000.00 | 7,749,355.92 | 0.53 |
| EUR/GBP | Currency sales | 6,700,000.00 | 7,622,731.67 | 0.52 |

Exchange rates

For the valuation of assets in a foreign currency, the following exchange rate for 31 March 2023 was used for conversion into Euro.

| Australian dollar | AUD | 1 | 1.6216 |
|-------------------|-----|---|------------|
| British pound | GBP | 1 | 0.8784 |
| Canadian dollar | CAD | 1 | 1.4700 |
| Danish krone | DKK | 1 | 7.4492 |
| Hong Kong dollar | HKD | 1 | 8.5271 |
| Japanese yen | JPY | 1 | 144.5539 |
| Norwegian krone | NOK | 1 | 11.3770 |
| South Korean won | KRW | 1 | 1,414.0367 |
| Swiss franc | CHF | 1 | 0.9922 |
| US dollar | USD | 1 | 1.0863 |

Notes on the report as at 31 March 2023 (appendix)

Significant accounting and valuation principles

The fund's accounts are kept in Euro.

The fund's semi-annual accounts were prepared based on the applicable classification and valuation principles in the country of domicile.

The price of securities and, if available, other exchange-listed derivatives reflects the relevant stock exchange or market value at the end of March 2023. Securities traded on a regulated market are valued at the market prices published for the relevant market. If Investments in target funds are made, these are valued at their most recent redemption prices.

If the fund holds OTC derivatives on the closing date, these are valued daily on the basis of indicative quotes from brokers or mathematical valuation models.

If the fund has pending forward exchange transactions, these are valued based on the forward rates applicable to the residual maturity.

Securities whose prices are not in line with market conditions and all assets for which no representative market value can be obtained are valued at a price established by the Management Company in good faith using recognised valuation rules.

Bank deposits and possibly existing fixed-term deposits were estimated at par value.

The assets and liabilities denominated in currencies other than the fund currency were converted to Euro on the basis of the exchange rate determined in the WM/Reuters fixing at 5 p.m. (4 p.m London time) of the trading day preceding the valuation day. Business transactions in foreign currencies are converted into the Fund currency at the time of recognition. Realised and unrealised foreign exchange gains and losses are recognised in profit or loss.

Dividends are posted as receivables on the date on which the respective securities are first quoted as "ex-dividend".

The fund shows various unit classes which participate in the fund's performance in proportion to the net asset value and after deduction of attributable expenses.

The issue or redemption price of the fund units are determined from the net asset value per unit on the respective valid trading days and, if relevant, plus any initial sales charge and/or redemption fee as defined in the sales prospectus. The initial sales charge shall be levied in favour of the Management Company and the sales agent and can be scaled according to the size of the order. The redemption fee is credited to the fund.

Taxation of the Fund

Fund assets are currently subject to a "taxe d'abonnement" of 0.05 % p.a. in Luxembourg, payable quarterly and based on the respective reported fund assets at the end of the quarter. Insofar as fund assets are invested in other Luxembourg investment funds that are already subject to the taxe d'abonnement, the portion of fund assets invested in such Luxembourg investment funds is exempt from this tax.

Income from the investments of the fund's assets will not be taxed in Luxembourg. However, it may be subject to withholding or other tax in the countries in which the fund assets are invested. Neither the Management Company nor the Depositary will obtain individual or collective receipts for such taxes.

Application of income

Further details on the use of income are contained in the sales prospectus.

Information on fees and expenses

The fees of the Management Company and the all-in fee are calculated based on the fund assets per calendar day and paid out on a monthly basis. The all-in fee covers the depositary fee, general custody and bearing fees for holding assets in custody, auditors' fees, costs of appointing proxies and costs of principal management activities, such as fund accounting and reporting. The calculation is based on a contractual agreement.

Individual unit-classes are subject tot a performance-related fee which is charged by the Management Company based on the terms defined in the prospectus.

If profit and loss includes other expenses, these expenses consist of the costs referred to in the prospectus, such as government fees, collateral management fees, or cost of changes to the prospectus.

Income and expenditure adjustment

Income and expenditure adjustments have been charged to the ordinary net income. These include net income generated during the reporting period, which purchasers of units pay as part of the issue price, and sellers of units receive in the redemption price.

Collateral

In conjunction with transactions in listed and/or OTC derivatives, the fund is required to provide or receive collateral in the form of bank deposits or securities.

If available, the positions "Other bank deposits/bank liabilities" include collateral provided/received by the fund in the form of bank deposits for listed derivatives and/or collateral provided for OTC derivatives. Collateral provided in the form of securities is recorded in the schedule of assets. Collateral received in the form of securities as well as collateral for OTC derivatives in the form of bank deposits are not recorded in the composition of the fund's assets and the schedule of assets.

As at 31 March 2023, the fund has lent securities as per the information provided in the list of assets. The fund has received collateral to the amount of the market value of the securities lent in the form of transferable securities or other liquid assets.

Soft commissions

The Management Company, in its role as the management company of the fund, may benefit from "soft commissions" (e.g. broker research, financial analyses, market and price information systems) in connection with trade transactions. Said commissions are used in the interests of unitholders when making investment decisions. Transactions of this type cannot be conducted with natural persons; the service providers concerned may trade only in the interests of the fund and the services provided must be directly associated with fund activities.

Significant events during the reporting period

In the concluded reporting period, the Fund UniValueFonds: Global made the following distribution:

for unit class A: EUR 1.05 per unit, ex date 10.11.2022

for unit class -net- A: EUR 0.64 per unit, ex date 10.11.2022

The unit class USD acc (WKN: A3CS18/ISIN: LU2355247086) underwent silent liquidation proceedings with effect from 1 March 2023.

Significant events after the reporting period

After the reporting period, there were no major changes or significant events.

Changes in the composition of the portfolio over the course of the year during the reporting period

During the reporting period, any changes made to the composition of the portfolio of the Fund over the course of the year are available free of charge upon request at the registered office of the Management Company.

General explanations in the context of the COVID-19 pandemic

Thanks to the development of effective vaccines and the spread of less dangerous virus variants, many countries have significantly reduced or lifted containment measures. However, China stuck to its zero-Covid policy over large parts of 2022 and reacted to the spread of the Omicron variant with repeated complete lockdowns of cities with millions of inhabitants. It was not until the end of the year that the government in Beijing reacted to the growing discontent among the population and surprisingly lifted the restrictions. The risks for the Chinese economy in 2023 are therefore likely to decrease. From a global perspective, the risks to economic growth resulting from the coronavirus have already gradually declined in the course of 2022. The Management Board of the Management Company continues to monitor the development of the capital markets in order to limit any economic impact on the fixed assets.

Explanation in the context of the Russia-Ukraine conflict

The invasion of Ukraine by Russian forces has significantly aggravated the geopolitical situation and led to Western sanctions against Russia. Russia has subsequently imposed counter-sanctions and sharply reduced the export of energy raw materials to Europe or even stopped them completely. In Europe, this has led to a sharp rise in inflation and a slump in economic activity. The Management Board of the management company monitors the development very closely. The assets have no financial exposure to Russia and Ukraine as of the reporting date.

Explanation in connection with banking risk

The fastest rate hikes by the major central banks in 60 years had an impact on stability in the financial markets and led to turmoil in the banking sector. Initially, after the insolvency of Silicon Valley Bank, a US specialist institution, had a major impact on the US regional banking sector following a large outflow of deposits, Credit Suisse came under pressure in Europe and, on the initiative of the Swiss authorities, was taken over by its competitor UBS at a fraction of its book value. In the course of this, the financial supervisory authority in Switzerland ordered a complete write-off of the nominal value of AT1 subordinated bonds. As a result, there is likely to be a repricing of banking risks in the equity and bond markets. The Management Board of the Management Company is monitoring the developments in order to limit possible consequences for the fixed assets here too.

Note on the Law of 17 December 2010

The fund was set up in accordance with Part I of the Luxembourg Law of 17 December 2010 relating to undertakings for collective investment ("Law of 17 December 2010") and fulfils the conditions laid down by Directive 2009/65/EC of the European Parliament and of the Council of 13 July 2009 on the coordination of legal and administrative provisions relating to undertakings for collective investment in transferable securities ("Directive 2009/65/EC").

Other information of the Management Company

Other information

Securities transactions are only ever carried out with counterparties included in a list of approved parties by the fund management. The list is reviewed on an ongoing basis. Criteria such as quality of execution, level of transaction costs, quality of research and reliability in the settlement of securities transactions are given precedence. Furthermore, the annual reports of the counterparties are examined.

Additional disclosures in accordance with Regulation (EU) 2015/2365 on securities financing transactions for the fund UniValueFonds: Global

| | Securities Lending | Repurchase Transactions | Total Return Swap |
|--|----------------------------------|----------------------------------|------------------------------|
| | | | |
| lsed assets | 20 020 024 02 | a st sourilise bla | |
| ibsolute | 29,020,824.03 | not applicable | not applicab |
| s a percentage of the fund's assets | 1.97 % | not applicable | not applicab |
| en largest counterparties ¹⁾ | | | |
| . Name | BNP Paribas Arbitrage SNC, Paris | not applicable | not applicab |
| . Gross volume of open transactions | 23,088,024.03 | not applicable | not applicab |
| I. Country of residence | France | not applicable | not applicab |
| 2. Name | Banco Santander S.A., Madrid | not applicable | not applicab |
| 2. Gross volume of open transactions | 5,932,800.00 | not applicable | not applicab |
| 2. Country of residence | Spain | not applicable | not applicab |
| Types of settlement and clearing (e.g. bilateral, trilateral, CCP) | | | |
| | trilateral | not applicable | not applicab |
| Fransactions sorted by remaining term (absolute amounts) | | | |
| ess than 1 day | not applicable | not applicable | not applicab |
| l day to 1 week (= 7 days) | not applicable | not applicable | not applicab |
| week to 1 month (= 30 days) | not applicable | not applicable | not applicab |
| 1 to 3 months | not applicable | not applicable | not applicab |
| 3 months to 1 year (= 365 days) | not applicable | not applicable | not applicab |
| nore than 1 year | not applicable | not applicable | not applicab |
| Inlimited | 29,020,824.03 | not applicable | not applicab |
| Type(s) and quality(ies) of the collateral received | | | |
| lypes | Equities | not applicable | not applicab |
| Qualities ²⁾ | A+ | not applicable | not applicab |
| | BBB+ | | |
| | BBB BB+ | | |
| | not rated | | |
| Currency(ies) of the collateral received | | | |
| | EUR HKD | not applicable | not applicab |
| Collectored and the server later descent (check de suma) | | | |
| Collateral sorted by remaining term (absolute sums) ess than 1 day | not applicable | not applicable | not applicab |
| | | | not applicab not applicab |
| l day to 1 week (= 7 days) l week to 1 month (= 30 days) | not applicable not applicable | not applicable | not applicab not applicab |
| to 3 months | | not applicable | not applicab not applicab |
| B months to 1 year (= 365 days) | not applicable not applicable | not applicable not applicable | not applicab |
| nore than 1 year | not applicable | not applicable | not applicab |
| inlimited | 29,666,935.79 | not applicable | not applicab |
| Income share and expenses | | | |
| The fund's income share | | | |
| bsolute | 15,243.79 | not applicable | not applicab |
| is a percentage of gross income | 58.28 % | not applicable | not applicab |
| he fund's expenses | 10,910.52 | not applicable | not applicab |
| of which Management Company expenses / income | | | |
| bsolute | 10,162.52 | not applicable | not applicab |
| is a percentage of gross income | 38.86 % | not applicable | not applicab |
| of which third-party expenses / income | | | |
| bsolute | 748.00 | not applicable | not applicab |
| is a percentage of gross income | 2.86 % | not applicable | not applicab |

Returns for the fund from reinvested cash collateral, calculated based on all securities financing transactions and total return swaps (absolute amount)

not applicable

Securities financing transactions and Total Return Swaps

Lended securities as a percentage of all the fund's lendable assets

2.07 %

Securities financing transactions and Total Return Swaps

The ten largest issuers of collateral, calculated based on all securities financing transactions and total return swaps ³⁾

| 1. Name | Valéo S.E. |
|---|--|
| 1. Volumes collateral received (absolute) | 15,380,855.55 |
| 2. Name | ENEL S.p.A. |
| 2. Volumes collateral received (absolute) | 8,142,461.90 |
| 3. Name | Siemens AG |
| 3. Volumes collateral received (absolute) | 5,553,241.80 |
| 4. Name | China Modern Dairy Holdings Ltd. |
| 4. Volumes collateral received (absolute) | 411,998.20 |
| 5. Name | China Lilang Ltd |
| 5. Volumes collateral received (absolute) | 178,376.32 |
| 6. Name | Golden Solar New Energy Technology Holdings Ltd. |
| 6. Volumes collateral received (absolute) | 1.63 |
| 7. Name | China Everbright Environment Group Ltd. |
| 7. Volumes collateral received (absolute) | 0.39 |

Reinvested collateral as a percentage of received collateral, calculated based on all securities financing transactions and total return swaps

No re-invested collateral; According to the sales prospect, a reinvestment of 100% is possible for bank deposits

Depositary / account manager for received collateral from securities financing transactions and total return swaps

Total number depositaries / account managers

| 1. Name | DZ PRIVATBANK S.A., Frankfurt |
|----------------------------|-------------------------------|
| 1. Deposit amount absolute | 29,666,935.79 |

Type of custody for issued collateral from securities financing transactions and total return swaps

As a percentage of all issued collateral from securities financing transactions and total return

| swaps | |
|---|----------------|
| separate accounts / securities accounts | not applicable |
| collective accounts / securities accounts | not applicable |
| other accounts / securities accounts | not applicable |
| Type of custody for certain recipients | not applicable |

1) Only actual fund counterparties are listed. The number of counterparties can be below 10.

2) Only assets which may be acquired for the Fund in accordance with the Law of 17 December 2010 and which meet the requirements of the relevant CSSF Circulars will be accepted as collateral. In addition to any bank deposits, such collateral includes highly liquid assets traded on a liquid market with transparent price fixing. The collateral provided is issued by issuers with high credit ratings. Additional information on collateral requirements can be found in the sales prospectus of the Fund.

3) Only actual fund securities issuers are listed. The number of issuers can be below 10.

1

Management and Organisation

Management Company and Main Management Company

Union Investment Luxembourg S.A. 3, Heienhaff L-1736 Senningerberg Grand Duchy of Luxembourg R.C.S.L. B 28679

Equity capital as at 31.12.2022: Euro 344.343 million after profit appropriation

LEI of the Management Company 529900FSORICM1ERBP05

Committee of Union Investment Luxembourg S.A.

Maria LÖWENBRÜCK Union Investment Luxembourg S.A. Luxembourg

Rolf KNIGGE Union Investment Luxembourg S.A. Luxembourg

Supervisory Board of Union Investment Luxembourg S.A.

Chairman of the Supervisory Board

Dr. Gunter HAUEISEN Union Asset Management Holding AG Frankfurt / Main

Other Members of the Supervisory Board

Dr. Carsten FISCHER Union Asset Management Holding AG Frankfurt / Main

Karl-Heinz MOLL Independent member of the Supervisory Board

Shareholders of Union Investment Luxembourg S.A.

Union Asset Management Holding AG Frankfurt / Main

Outsourcing of portfolio management to the following companies belonging to the Union Investment Group:

Union Investment Privatfonds GmbH Weißfrauenstraße 7 D-60311 Frankfurt / Main

Union Investment Institutional GmbH Weißfrauenstraße 7 D-60311 Frankfurt / Main

Auditor (Réviseur d'entreprises agréé)

PriceWaterhouseCoopers, Société coopérative 2, rue Gerhard Mercator L-2182 Luxembourg

also the auditor of Union Investment Luxembourg S.A.

Depositary and Main Paying Agent

DZ PRIVATBANK S.A. 4, rue Thomas Edison L-1445 Strassen Grand Duchy of Luxembourg

Paying and sales agent in the Grand Duchy of Luxembourg

DZ PRIVATBANK S.A. 4, rue Thomas Edison L-1445 Strassen Grand Duchy of Luxembourg

Paying Agent, Distributor and Information Agent in the Federal Republic of Germany

DZ BANK AG Deutsche Zentral-Genossenschaftsbank Platz der Republik D-60265 Frankfurt / Main Registered Office: Frankfurt / Main

Further Distributors in the Federal Republic of Germany

Credit institutes affiliated with DZ Bank AG are others sales offices in the Federal Republic of Germany.

Additional information for investors in Austria

Institution within the meaning of Article 92(1)(a), (b), (d) and (e) of Directive 2009/65/EC (UCITS) - Distributor and Paying Agent:

VOLKSBANK WIEN AG Dietrichgasse 25 A-1030 VIENNA Email: filialen@volksbankwien.at

The sales prospectus with the investment terms and conditions and the Key Investor Information Document ("KIID"), the annual and semi-annual reports as well as the issue and redemption prices for this Fund are available from VOLKSBANK WIEN AG and other information and documents may be inspected.

In addition, VOLKSBANK WIEN AG will forward certain payments to unitholders on their behalf and process subscriptions and redemptions of units as soon as it receives the corresponding subscription and redemption orders.

All of the funds and/or investment companies currently authorised for public distribution in Austria and managed by Union Investment Luxembourg S.A. can be viewed on the Union Investment website at www.union-investment.com, which is intended for unit holders and shareholders resident in Austria.

Important notices to unitholders shall be published in the official gazette "Amtsblatt zur Wiener Zeitung" in the cases prescribed by the Austrian Investment Fund Act of 2011 as well as on the website www.union-investment.com, which is intended for unitholders and shareholders resident in Austria.

Institution within the meaning of Article 92(1)(c) and (f) of Directive 2009/65/EC (UCITS) - Contact point for communication with the relevant authorities:

Union Investment Luxembourg S.A. 3, Heienhaff L-1736 Senningerberg

The information on dealing with investor complaints and the exercise of investor rights arising from investments in these funds will also be made available by Union Investment Luxembourg S.A.

Union Investment Luxembourg S.A. 3, Heienhaff L-1736 Senningerberg service@union-investment.com privatkunden.union-investment.de



